Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

(2020) Abhishek Maiti et al.   BLOOD

Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial

(2020) Andrew Henry Wei et al.   BLOOD

Relation between measurable residual disease and morphologic relapse in AML.

(2020) Lauren Shih et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

(2020) Courtney D DiNardo et al.   Lancet Haematology

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

(2020) Abhishek Maiti et al.   AMERICAN JOURNAL OF HEMATOLOGY

How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?

(2019) Nicholas J. Short et al.   HAEMATOLOGICA

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia

(2018) Mithun Vinod Shah et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

(2018) Courtney D DiNardo et al.   LANCET ONCOLOGY

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

(2018) Mojca Jongen-Lavrencic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse

(2017) P Boddu et al.   LEUKEMIA

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Assessment of Minimal Residual Disease in Standard-Risk AML

(2016) Adam Ivey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

(2013) Sylvie D. Freeman et al.   JOURNAL OF CLINICAL ONCOLOGY